Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2026)

Lyell Immunopharma's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $31.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1.0% year-over-year to $31.5 million; the TTM figure through Mar 2026 stood at $31.5 million (up 1.0% YoY), while the FY2025 annual figure was $46.5 million, up 13.96% from the prior year.
• Accumulated Expenses came in at $31.5 million for Q1 2026 at Lyell Immunopharma, down from $46.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $46.5 million in Q4 2025 to a low of $21.4 million in Q2 2022.
• A 5-year average of $28.7 million and a median of $28.1 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses fell 16.32% in 2022 and jumped 45.14% in 2024, its largest moves.
• Lyell Immunopharma's Accumulated Expenses stood at $28.8 million in 2022, then dropped by 2.19% to $28.1 million in 2023, then jumped by 45.14% to $40.8 million in 2024, then increased by 13.96% to $46.5 million in 2025, then slumped by 32.33% to $31.5 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $31.5 million, $46.5 million, and $29.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison